Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -177.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $13M | $77M | $54M | $257M | $1.0B | $1.0B | — |
| Enterprise Value | $6M | $18M | $82M | $16M | $157M | $854M | $1.0B | — |
| P/E Ratio → | -0.02 | — | — | — | 50.08 | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.10 | 1.31 | 1.66 | 0.55 | 2.32 | 12.35 | 61.94 | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 29.28 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -177.5% | -177.5% | -87.4% | -68.0% | 5.3% | -70.5% | -79.3% | -59.6% |
| ROA | -115.0% | -115.0% | -67.4% | -54.6% | 3.2% | -35.3% | -75.4% | -56.9% |
| ROIC | -116.2% | -116.2% | -90.2% | -171.6% | — | — | -141.9% | — |
| ROCE | -134.6% | -134.6% | -77.1% | -66.0% | -52.1% | -39.7% | -79.4% | -62.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.79 | 0.79 | 0.30 | 0.15 | 0.14 | 0.02 | 0.01 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.53 | 0.09 | -0.39 | -0.91 | -2.07 | -0.99 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -2841.84 | 26.79 | -394.58 | -4328.33 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.97 | 2.97 | 6.74 | 13.87 | 14.35 | 28.56 | 21.04 | 25.30 |
| Quick Ratio | 2.97 | 2.97 | 6.74 | 13.87 | 14.35 | 28.56 | 21.04 | 25.30 |
| Cash Ratio | 2.51 | 2.51 | 6.40 | 13.49 | 13.85 | 27.78 | 20.72 | 24.89 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 2.0% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $6M | $6M | $5M | $4M | $3M | $3M | $5M |
Imminent liquidity insolvency risk
According to recent market data, the company's price-to-book ratio has compressed to 0.12, a level that suggests investors are pricing in a high probability of total equity impairment rather than future growth potential, especially when compared to the premium multiples commanded by established peers like Intuitive Surgical.
The current valuation multiples are effectively meaningless in a traditional sense, as the lack of revenue renders P/E and P/S metrics non-calculable. This deep discount to book value indicates that the market views the company's intellectual property and hardware assets as having little residual value outside of a potential fire-sale or acquisition scenario.
Based on reported financial statements, the company's ROIC has deteriorated significantly, reaching -46.8% in 2026Q1, which highlights the severe inefficiency of capital deployment as the firm continues to consume its remaining cash reserves without achieving any meaningful commercial milestones or revenue-generating operational scale.
The consistent decline in return on invested capital over the last ten quarters reflects a business model that is currently destroying value rather than compounding it. Without a clear path to commercialization, these negative returns suggest that every dollar of capital raised is being eroded by high R&D costs and administrative overhead.
As reported in recent SEC filings, the company's current ratio has fallen to 1.54 in 2026Q1, a sharp decline from the 17.16 observed in 2024Q1, signaling that the firm's ability to cover short-term obligations is rapidly diminishing as cash reserves are depleted by ongoing development activities.
The rapid contraction in liquidity ratios leaves the company with virtually no margin for error regarding regulatory delays or unexpected operational costs. Investors should monitor the cash balance closely, as the current trajectory suggests that the firm may be forced into highly dilutive financing or restructuring in the immediate future.
According to the latest balance sheet data, the debt-to-equity ratio has surged to 1.91 in 2026Q1, up from 0.15 in 2023Q4, which indicates an increasing reliance on debt financing even as the company's equity base is being rapidly eroded by persistent and substantial quarterly net losses.
The shift toward higher leverage in a pre-revenue environment is particularly concerning, as it introduces interest-bearing obligations that the company is currently ill-equipped to service. This trend suggests that management is exhausting all available capital sources to sustain operations, which significantly elevates the risk of a total loss for common shareholders.
Based on industry analysis, the most commonly misapplied metric for this business model is the price-to-sales ratio, which obscures the company's lack of commercial viability and ignores the reality that the firm is currently a pre-revenue entity with no established product-market fit or recurring revenue streams.
Using P/S or similar growth-oriented multiples for a company in this stage of development is fundamentally flawed because it assumes a revenue base that does not exist. Analysts should instead focus on the cash-burn-to-milestone ratio, which provides a more accurate assessment of the company's survival probability and the urgency of its capital requirements.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RBOT stock.
Vicarious Surgical Inc.'s current P/E ratio is -0.0x. The historical average is 50.1x.
Vicarious Surgical Inc.'s return on equity (ROE) is -177.5%. The historical average is -76.7%.
Based on historical data, Vicarious Surgical Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.